✨ Free AI Report
Verastem Oncology: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Verastem Oncology
Research Preview

Verastem Oncology: Business Overview, Financials & Competitive Analysis

Verastem Oncology is a biopharmaceutical company committed to developing and commercializing new medicines for RAS/MAPK pathway-driven cancers, with its pipeline focused on novel small molecule drugs including RAF/MEK...

Analyst-debate audio for Verastem Oncology

AskCyborg analysts argue the bull and bear cases for Verastem Oncology across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Verastem Oncology OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
7/ 10Strong

Cyborg Score thesis

Rare oncology pure-play with first commercial product, promising pipeline, and sufficient capital for multi-year value...

Read the full analyst-debate transcript →
Industry Biopharmaceutical / Precision Oncology
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Verastem Oncology Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Verastem Oncology Overview

Pro stress-test →

Verastem Oncology is a biopharmaceutical company committed to developing and commercializing new medicines for RAS/MAPK pathway-driven cancers, with its pipeline focused on novel small molecule drugs including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. The company transitioned to commercial-stage status with the launch of AVMAPKI FAKZYNJA CO-PACK, the first treatment specifically approved by the FDA for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC).

Strategic Profile

Pro stress-test →

Verastem anticipates the LGSOC commercial launch and development program will be self-sustaining by the second half of 2026. The company is focused on maximizing commercial penetration of its approved product while advancing VS-7375, a KRAS G12D inhibitor with potential best-in-class positioning across multiple solid tumor indications including pancreatic and non-small cell lung cancers.

Competitive Landscape

Pro stress-test →

Verastem operates in the precision oncology space competing against larger pharma companies developing RAS/MAPK pathway inhibitors. Key competitive areas include KRAS-targeted therapies where companies like Mirati (MRTX) and Amgen have competing G12C inhibitors, and broader oncology companies. Verastem's differentiation lies in its specialized focus on KRAS G12D and combination approaches, particularly in lower-incidence tumors where it can establish category leadership.

Industry Context

Verastem Oncology operates in Biopharmaceutical / Precision Oncology.

Key facts

Founded: 2007 · Headquarters: Boston, MA, United States · Revenue: $30.9M (2025 preliminary)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Verastem Oncology.

+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Verastem Oncology has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

KRAS G12C InhibitorsCompeting KRAS G12C inhibitor programs in NSCLC→Ovarian Cancer TreatmentsBroader competitive landscape in ovarian cancer but limited specific LGSOC competition→RAF/MEK Pathway ProgramsCompeting approaches to RAS/MAPK pathway inhibition→

Compare Verastem Oncology with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Verastem Oncology operates in Biopharmaceutical / Precision Oncology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical / Precision Oncology research →
NEW · MCP server

Ask your AI assistant about Verastem Oncology

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Verastem Oncology and its top competitor on Cyborg Score”
“What did Verastem Oncology do this quarter?”
“Is Verastem Oncology a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Verastem Oncology do?+
Verastem Oncology is a biopharmaceutical company committed to developing and commercializing new medicines for RAS/MAPK pathway-driven cancers, with its pipeline focused on novel small molecule drugs including RAF/MEK...
What is Verastem Oncology's Cyborg Score?+
Verastem Oncology has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Verastem Oncology's main competitors?+
Named competitors include KRAS G12C Inhibitors, Ovarian Cancer Treatments, RAF/MEK Pathway Programs. The full competitive landscape is in the AskCyborg report.
How can I get the full Verastem Oncology research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Verastem Oncology research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Verastem Oncology over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score